Enanta Pharmaceuticals, Inc.’ HCV NS5A Inhibitor EDP-239 Advances Into Combination Studies With Alisporivir (DEB025)
8/7/2014 10:32:22 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Novartis has advanced EDP-239, Enanta’s NS5A inhibitor for hepatitis C virus (HCV), into drug combination studies with alisporivir (DEB025), a cyclophilin inhibitor being developed by Novartis. These combination studies are part of Enanta’s existing collaboration with Novartis for the development of new combination therapies for the treatment of HCV using Enanta’s NS5A inhibitors.
Help employers find you! Check out all the jobs and post your resume
comments powered by